Complete Filing Data
NewAmsterdam Pharma Co N.V. reported Stockholders Equity of $683.43 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean NewAmsterdam Pharma Co N.V. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Net Income * | -$203.8M | -$241.6M | -$176.9M | -$22.6M | -$41.8M | -$5.7M |
| Selling General And Administrative Expense | $106.4M | $70.4M | $37.6M | $19.5M | $6.0M | $1.4M |
| Research And Development Expense | $141.8M | $151.4M | $159.4M | $86.7M | $29.0M | $4.0M |
| Comprehensive Income Net Of Tax | -$203.5M | -$241.6M | -$176.9M | -$11.5M | -$41.5M | |
| Operating Income Loss | -$225.7M | -$176.3M | -$183.0M | -$3.6M | -$35.0M | |
| Operating Expenses | $248.2M | $221.9M | $197.1M | $106.3M | $35.0M | |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$203.8M | -$241.6M | -$176.9M | -$22.6M | -$41.8M | |
| Revenue From Contract With Customer Excluding Assessed Tax | $22.5M | $45.6M | $14.1M | $102.7M | ||
| Deferred Revenue Current | $4.0M | $6.0M | $8.9M | $13.9M | ||
| Profit Loss From Operating Activities | -$67.6M | -$29.8M | -$5.4M | |||
| Profit Loss Before Tax | -$78.1M | -$28.6M | -$5.7M | |||
| Comprehensive Income | -$78.1M | -$28.6M | -$5.7M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$72.0M | -$17.4M | -$39.5M | -$16.6M | -$39.0M | -$93.8M | -$38.3M | -$42.0M | |
| Selling General And Administrative Expense | $24.5M | $27.3M | $27.2M | $18.4M | $16.5M | $14.5M | $9.1M | $9.9M | $8.1M |
| Research And Development Expense | $31.0M | $27.5M | $44.8M | $35.7M | $38.4M | $42.4M | $43.4M | $34.3M | $40.4M |
| Comprehensive Income Net Of Tax | -$71.7M | -$17.5M | -$39.6M | -$16.6M | -$39.0M | -$93.8M | -$47.1M | -$38.3M | -$42.0M |
| Operating Income Loss | -$55.1M | -$35.6M | -$68.9M | -$25.0M | -$52.6M | -$55.5M | -$49.6M | -$42.5M | -$39.9M |
| Operating Expenses | $55.5M | $54.8M | $71.9M | $54.1M | $54.9M | $56.9M | $52.5M | $44.2M | $48.5M |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$72.0M | -$17.4M | -$39.5M | -$16.6M | -$39.0M | -$93.8M | -$47.1M | -$38.3M | -$42.0M |
| Revenue From Contract With Customer Excluding Assessed Tax | $348.0K | $19.1M | $3.0M | $29.1M | $2.3M | $1.4M | $2.9M | $1.7M | $8.6M |
| Deferred Revenue Current | $3.0M | $4.5M | $6.1M | $8.1M | |||||
| Profit Loss From Operating Activities | |||||||||
| Profit Loss Before Tax | |||||||||
| Comprehensive Income |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Stockholders Equity | $683.4M | $757.5M | $288.4M | $430.1M | -$113.8M | -$73.0M | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $491.3M | $771.7M | $340.5M | $467.7M | $60.1M | $9.6M | |
| Assets | $769.3M | $864.6M | $347.1M | $478.5M | $59.8M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$293.2M | $438.1M | -$132.3M | $402.3M | $55.2M | ||
| Retained Earnings Accumulated Deficit | -$762.4M | -$558.6M | -$317.0M | -$140.0M | |||
| Property Plant And Equipment Net | $383.0K | $242.0K | $46.0K | $34.0K | |||
| Prepaid Expense And Other Assets Current | $38.1M | $24.3M | $6.3M | $10.3M | |||
| Operating Lease Right Of Use Asset | $185.0K | $431.0K | $55.0K | $120.0K | |||
| Operating Lease Liability Current | $136.0K | $246.0K | $60.0K | $66.0K | |||
| Liabilities Current | $85.8M | $106.9M | $49.9M | $36.1M | |||
| Liabilities And Stockholders Equity | $769.3M | $864.6M | $347.1M | $478.5M | |||
| Liabilities | $85.9M | $107.1M | $58.7M | $48.4M | |||
| Intangible Assets Net Including Goodwill | $407.0K | $534.0K | $170.0K | $208.0K | |||
| Equity | $683.4M | $757.5M | $288.4M | $430.1M | -$113.8M | -$73.0M | |
| Derivative Liabilities Current | $57.3M | $37.5M | $12.6M | $4.1M | |||
| Common Stock Value | $14.3M | $13.4M | $10.2M | $10.1M | |||
| Cash And Cash Equivalents | $438.5M | $53.1M | $7.9M | $2.5M | |||
| Assets Current | $675.7M | $863.4M | $346.8M | $478.0M | |||
| Additional Paid In Capital Common Stock | $1.43B | $1.30B | $590.8M | $555.6M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $4.8M | $4.5M | $4.4M | $4.4M | |||
| Accounts Payable Current | $9.0M | $4.7M | $16.9M | $11.9M | |||
| Accounts Payable And Other Accrued Liabilities Current | $15.4M | $13.6M | $11.4M | $6.1M | |||
| Cash | $490.0M | $771.7M | $340.5M | ||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $13.0K | $20.0K | $13.0K | ||||
| Cash Flows From Used In Operating Activities | $8.0M | -$25.2M | -$6.0M | ||||
| Cash Flows From Used In Investing Activities | $715.0K | -$20.0K | -$13.0K | ||||
| Cash Flows From Used In Financing Activities | $375.2M | $69.0M | $11.3M | ||||
| Adjustments For Increase Decrease In Other Operating Payables | -$2.1M | $8.2M | $829.0K | ||||
| Adjustments For Decrease Increase In Other Operating Receivables | -$4.0M | -$4.4M | -$1.4M | ||||
| Property Plant And Equipment | $144.0K | $190.0K | $12.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $728.1M | $778.5M | $777.4M | $378.9M | $387.4M | $411.8M | $331.8M | $373.3M | $398.4M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $539.7M | $563.9M | $748.4M | $422.7M | $430.7M | $481.1M | $368.3M | $416.7M | $441.3M |
| Assets | $786.4M | $815.1M | $818.4M | $439.2M | $446.7M | $488.5M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$27.1M | $143.2M | -$29.5M | ||||||
| Retained Earnings Accumulated Deficit | -$687.5M | -$615.5M | -$598.1M | -$466.4M | -$449.7M | -$410.7M | |||
| Property Plant And Equipment Net | $323.0K | $312.0K | $238.0K | $231.0K | $234.0K | $101.0K | |||
| Prepaid Expense And Other Assets Current | $28.1M | $30.7M | $8.8M | $15.1M | $14.6M | $6.7M | |||
| Operating Lease Right Of Use Asset | $246.0K | $308.0K | $369.0K | $493.0K | $554.0K | $38.0K | |||
| Operating Lease Liability Current | $181.0K | $225.0K | $252.0K | $240.0K | $234.0K | $43.0K | |||
| Liabilities Current | $58.3M | $36.5M | $40.9M | $41.3M | $45.3M | $59.7M | |||
| Liabilities And Stockholders Equity | $786.4M | $815.1M | $818.4M | $439.2M | $446.7M | $488.5M | |||
| Liabilities | $58.4M | $36.6M | $41.1M | $60.3M | $59.3M | $76.7M | |||
| Intangible Assets Net Including Goodwill | $439.0K | $470.0K | $502.0K | $593.0K | $542.0K | $486.0K | |||
| Equity | $728.1M | $778.5M | $777.4M | $378.9M | $387.4M | $411.8M | $331.8M | $373.3M | $398.4M |
| Derivative Liabilities Current | $44.4M | $20.9M | $23.5M | $18.9M | $23.5M | $33.1M | |||
| Common Stock Value | $14.1M | $14.0M | $14.0M | $11.4M | $11.2M | $11.1M | |||
| Cash And Cash Equivalents | |||||||||
| Assets Current | $732.3M | $769.9M | $817.3M | $437.9M | $445.4M | $487.8M | |||
| Additional Paid In Capital Common Stock | $1.40B | $1.38B | $1.36B | $829.4M | $821.6M | $807.0M | |||
| Accumulated Other Comprehensive Income Loss Net Of Tax | $4.6M | $4.3M | $4.4M | $4.4M | $4.4M | $4.4M | |||
| Accounts Payable Current | $3.6M | $5.9M | $6.1M | $7.0M | $5.3M | $8.5M | |||
| Accounts Payable And Other Accrued Liabilities Current | $10.1M | $9.5M | $8.0M | $10.6M | $10.2M | $10.0M | |||
| Cash | $538.4M | $563.9M | $748.4M | $422.7M | |||||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | |||||||||
| Cash Flows From Used In Operating Activities | |||||||||
| Cash Flows From Used In Investing Activities | |||||||||
| Cash Flows From Used In Financing Activities | |||||||||
| Adjustments For Increase Decrease In Other Operating Payables | |||||||||
| Adjustments For Decrease Increase In Other Operating Receivables | |||||||||
| Property Plant And Equipment |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Share Based Compensation | $59.4M | $33.6M | $24.6M | $4.1M | $1.2M | |
| Payments To Acquire Productive Assets | $246.0K | $672.0K | $24.0K | $221.0K | $24.0K | |
| Net Cash Provided By Used In Operating Activities | -$147.8M | -$158.6M | -$141.2M | $10.7M | -$29.5M | |
| Net Cash Provided By Used In Investing Activities | -$174.9M | -$62.8M | -$24.0K | -$221.0K | -$24.0K | |
| Net Cash Provided By Used In Financing Activities | $29.5M | $659.5M | $8.9M | $391.9M | $84.7M | |
| Increase Decrease In Prepayments And Other Receivables | $13.3M | $17.5M | -$4.0M | $4.2M | $5.2M | |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | $2.4M | $1.7M | $5.5M | -$8.7M | $3.1M | |
| Increase Decrease In Accounts Payable | $4.9M | -$12.9M | $5.1M | $4.8M | $6.6M | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $12.8M | -$6.8M | $5.1M | $5.2M | -$4.7M | |
| Depreciation Depletion And Amortization | $220.0K | $113.0K | $49.0K | $9.0K | $5.0K | |
| Increase Decrease In Deferred Revenue | -$2.0M | -$4.0M | -$8.7M | $18.4M | ||
| Proceeds From Warrant Exercises | $1.6M | $13.8M | $8.6M | |||
| Proceeds From Stock Options Exercised | $29.5M | $1.8M | $290.0K | |||
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | $383.9M | $43.8M | $5.3M | |||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | $1.6M | $1.4M | $24.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|
| Share Based Compensation | $15.2M | $7.9M | $7.6M |
| Payments To Acquire Productive Assets | $16.0K | $385.0K | $7.0K |
| Net Cash Provided By Used In Operating Activities | -$36.5M | -$54.6M | -$31.9M |
| Net Cash Provided By Used In Investing Activities | $2.9M | -$385.0K | -$7.0K |
| Net Cash Provided By Used In Financing Activities | $6.5M | $198.2M | $2.4M |
| Increase Decrease In Prepayments And Other Receivables | -$16.0M | -$956.0K | $1.4M |
| Increase Decrease In Accrued Liabilities And Other Operating Liabilities | -$5.0M | -$1.4M | $7.0M |
| Increase Decrease In Accounts Payable | $2.3M | -$8.3M | -$2.9M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $3.8M | -$2.5M | $3.1M |
| Depreciation Depletion And Amortization | $52.0K | $15.0K | $9.0K |
| Increase Decrease In Deferred Revenue | -$3.0M | -$1.4M | -$3.2M |
| Proceeds From Warrant Exercises | $183.0K | $8.8M | $2.4M |
| Proceeds From Stock Options Exercised | $7.9M | $440.0K | |
| Increase Decrease In Cash And Cash Equivalents Before Effect Of Exchange Rate Changes | |||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Earnings Per Share Diluted | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-3.81 | |
| Earnings Per Share Basic | $-1.72 | $-2.56 | $-2.15 | $-1.19 | $-3.81 | |
| Common Stock Shares Outstanding | 114.4M | 108.1M | 82.5M | 81.6M | ||
| Common Stock Par Or Stated Value Per Share | $0.12 | $0.12 | $0.12 | $0.12 | ||
| Common Stock Shares Issued | 114.4M | 108.1M | 82.5M | 81.6M | ||
| Common Stock Shares Authorized | 400.0M | 400.0M | 400.0M | 400.0M | ||
| Diluted Earnings Loss Per Share | $-0.96 | $-1.19 | $-0.54 | |||
| Basic Earnings Loss Per Share | $-0.96 | $-1.19 | $-0.54 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share Diluted | $-0.61 | $-0.15 | $-0.34 | $-0.18 | $-0.41 | $-1.06 | $-0.57 | $-0.47 | $-0.51 |
| Earnings Per Share Basic | $-0.61 | $-0.15 | $-0.34 | $-0.18 | $-0.41 | $-1.06 | $-0.57 | $-0.47 | $-0.51 |
| Common Stock Shares Outstanding | 113.2M | 112.5M | 112.2M | 92.2M | 90.0M | 89.7M | |||
| Common Stock Par Or Stated Value Per Share | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | $0.12 | |||
| Common Stock Shares Issued | 113.2M | 112.5M | 112.2M | 92.2M | 90.0M | 89.7M | |||
| Common Stock Shares Authorized | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | 400.0M | |||
| Diluted Earnings Loss Per Share | |||||||||
| Basic Earnings Loss Per Share |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $59.4M | $33.7M | $24.8M | $4.3M | $718.0K | |
| Foreign Currency Transaction Gain Loss Before Tax | $13.1M | -$6.6M | $5.1M | -$9.7M | $1.7M | |
| Stock Issued During Period Value Warrants Exercised | $4.7M | $27.8M | $10.2M | |||
| Investment Income Interest | $27.6M | $16.9M | $11.3M | |||
| Noncash Rent Expense | $12.0K | $6.0K | $10.0K | $2.0K | ||
| Change In Fair Value Of Derivative Earnout And Warrants | $18.8M | $75.6M | $10.3M | $1.0M | ||
| Change In Fair Value Of Warrants | $22.8M | $38.6M | $10.0M | $334.0K | ||
| Change In Fair Value Of Earnout | -$4.0M | $37.0M | $266.0K | $707.0K | ||
| Stock Issued During Period Value Stock Options Exercised | $24.5M | $5.7M | $290.0K | |||
| Operating Expense | $165.1M | $29.8M | $5.4M | |||
| Gains Losses On Exchange Differences On Translation Before Tax | -$9.3M | $1.4M | -$24.0K | |||
| Finance Costs | $271.0K | $216.0K | $344.0K | |||
| Adjustments For Unrealised Foreign Exchange Losses Gains | $9.3M | -$1.4M | -$24.0K | |||
| Adjustments For Depreciation And Amortisation Expense | $72.0K | $14.0K | $1.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $15.0M | $15.2M | $15.2M | $8.0M | $8.3M | $8.0M | $5.4M | $5.6M | $7.7M |
| Foreign Currency Transaction Gain Loss Before Tax | $218.0K | $8.6M | $4.3M | $4.7M | -$994.0K | -$2.4M | -$3.2M | -$72.0K | $3.1M |
| Stock Issued During Period Value Warrants Exercised | $637.0K | $2.0K | $412.0K | $6.3M | $19.8M | $1.0K | $7.5M | $2.7M | |
| Investment Income Interest | $6.7M | $7.1M | $7.4M | $4.4M | $4.9M | $3.1M | $3.1M | $4.6M | $943.0K |
| Noncash Rent Expense | $3.0K | $1.0K | $2.0K | ||||||
| Change In Fair Value Of Derivative Earnout And Warrants | -$17.8M | $39.0M | $6.2M | ||||||
| Change In Fair Value Of Warrants | $23.8M | -$2.6M | -$13.8M | -$4.6M | -$6.6M | $30.2M | |||
| Change In Fair Value Of Earnout | -$4.0M | $5.4M | -$3.1M | $8.7M | |||||
| Stock Issued During Period Value Stock Options Exercised | $58.0K | -$549.0K | $185.0K | $105.0K | |||||
| Operating Expense | |||||||||
| Gains Losses On Exchange Differences On Translation Before Tax | |||||||||
| Finance Costs | |||||||||
| Adjustments For Unrealised Foreign Exchange Losses Gains | |||||||||
| Adjustments For Depreciation And Amortisation Expense |
Most recent annual filing with the SEC: February 18, 2026
Data sourced from SEC EDGAR public filings as of August 6, 2026.